Table 3.
Summary of clinical events of interest diagnosed on a day of caffeine citrate exposure by site
| Site 1 (N=100) |
Site 2 (N=108) |
Site 3 (N=107) |
Site 4 (N=95) |
Total (N=410) |
|
|---|---|---|---|---|---|
| Death | 0% | 2% | 4% | 3% | 2% |
| BPDa, b | 49% | 27% | 29% | 40% | 37% |
| Medical NEC | 1% | 8% | 4% | 5% | 5% |
| Surgical NEC | 4% | 3% | 8% | 3% | 4% |
| SIP | 5% | 7% | 5% | 2% | 5% |
| Grade II IVHb | 7% | 7% | 8% | 7% | 7% |
| Grade III or IV IVHb | 17% | 9% | 14% | 11% | 13% |
| PDA ligation | 14% | 19% | 8% | 6% | 12% |
| Seizures | 2% | 8% | 2% | 0% | 3% |
| Arrhythmia | 0% | 0% | 0% | 0% | 0% |
a
Per BPD definition, participants discharged or transferred from hospital before 36 weeks of PMA are excluded from this analysis.
b
All BPD and IVH (grade II, III, or IV) are included in this analysis regardless of whether the infant was receiving caffeine on the day of the event.
BPD: bronchopulmonary dysplasia; IVH: intraventricular hemorrhage; NEC: necrotizing enterocolitis; PDA: patent ductus arteriosus; SIP: spontaneous intestinal perforation.